Unverified record. The outcome below was
inferred from the share-price reaction around this date. Nobody has confirmed it against an FDA, SEC or company document, and it may be wrong: we have published at least one inferred outcome that turned out to be impossible (see
corrections ). Treat it as a price observation, not as a regulatory fact. Verified decisions on this site always link a primary source.
APTO FDA Decision outcome unverified · 2025-02-20 Rebuilt daily · next FDA decision on the calendar
Price into the decision (T-120) $11.99 $4.86 Historical price action; green = local high, red = low/sell-off.
Decision facts FDA decision date 2025-02-20
Outcome Unconfirmed · price consistent with approval ~ price-only (validating)
Decision-day move +26.7%
T-120 run-up (low→high) +3.0% ($4.5→$12.0)
Validation Outcome consistent with price; primary-source verification in progress.
See the full 2026 PDUFA calendar → Not affiliated with or endorsed by the FDA. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.